eFFECTOR's lead lung cancer program falls through, stock crashes
04 Apr 2024
Phase 2Clinical Result
eFFECTOR Therapeutics won’t be moving its lead candidate forward in frontline non-small cell lung cancer after its experimental drug failed a Phase 2 study.
In the KICKSTART trial, patients with PD-L1 ≥50% received Merck’s Keytruda with either tomivosertib or placebo as frontline treatment. Median progression-free survival in the tomivosertib arm was 13 weeks compared to 11.7 weeks with placebo, and the difference was not statistically significant, eFFECTOR reported on Thursday. Overall survival data were immature, but there was no trend favoring the experimental arm.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.